Twist Bioscience (NASDAQ:TWST – Get Free Report) is set to release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Twist Bioscience to post earnings of ($0.84) per share for the quarter. Twist Bioscience has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.03. The company had revenue of $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. Twist Bioscience’s revenue for the quarter was up 31.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.74) EPS. On average, analysts expect Twist Bioscience to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Twist Bioscience Stock Performance
NASDAQ:TWST opened at $32.03 on Tuesday. Twist Bioscience has a 1 year low of $11.46 and a 1 year high of $43.21. The stock has a market cap of $1.85 billion, a P/E ratio of -8.87 and a beta of 1.62. The stock has a 50-day simple moving average of $34.40 and a 200-day simple moving average of $30.68.
Insider Transactions at Twist Bioscience
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Barclays dropped their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Scotiabank upped their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research note on Monday, February 5th.
Check Out Our Latest Stock Analysis on TWST
About Twist Bioscience
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
- Five stocks we like better than Twist Bioscience
- Where Do I Find 52-Week Highs and Lows?
- 3 Trend-Following Entries for Income Investors
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stocks Mega Investors Are Buying
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Can Disney Stock Triple Before 2030?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.